BioVie Inc

About

BioVie Inc is a pharmaceutical development company based in Carson City, Nevada, specializing in innovative therapeutic solutions for complex neurological and inflammatory conditions. The company focuses on developing novel compounds targeting Alzheimer's disease, Parkinson's disease, Long COVID, ascites, and longevity applications through advanced epigenetic research. BioVie has developed bezisterim (NE3107), a proprietary investigational molecule designed to selectively modulate inflammation while enhancing brain energy transfer and insulin sensitivity. This unique approach addresses inflammation as a central mechanism in neurodegenerative disease progression. The company also advances BIV201, another promising therapeutic compound in its development pipeline. The organization employs cutting-edge pharmaceutical research methodologies, including DNA methylation measurement and epigenetic mechanisms analysis, to create targeted interventions that could potentially alter disease trajectories. BioVie integrates comprehensive drug discovery, preclinical development, and clinical trial management capabilities within its operations. As a publicly traded pharmaceutical company, BioVie maintains rigorous regulatory compliance standards while advancing its therapeutic portfolio through systematic clinical development programs. The company emphasizes patient-centered innovation, aiming to provide hope and empower individuals to take control of their health outcomes. BioVie combines scientific excellence with strategic therapeutic focus, positioning itself as an emerging leader in neuroinflammation research and pharmaceutical manufacturing dedicated to addressing critical unmet medical needs in neurodegenerative diseases.